Long-term efficacy and safety of secukinumab in Japanese patients with moderate to severe plaque psoriasis: 3-year results of a double-blind extension study

The Journal of Dermatology ◽

10.1111/1346-8138.14761 ◽

2019 ◽

Vol 46 (3) ◽

pp. 186-192 ◽

Author(s):

Yukari Okubo ◽

Mamitaro Ohtsuki ◽

Akimichi Morita ◽

Masako Yamaguchi ◽

Tomohiro Shima ◽

...

Keyword(s):

Plaque Psoriasis ◽

Japanese Patients ◽

Extension Study ◽

Efficacy And Safety ◽

Double Blind ◽

Severe Plaque Psoriasis ◽

Download Full-text

Long‐term efficacy and safety of tildrakizumab in Japanese patients with moderate to severe plaque psoriasis: Results from a 5‐year extension of a phase 3 study (reSURFACE 1)

The Journal of Dermatology ◽

10.1111/1346-8138.15763 ◽

2021 ◽

Author(s):

Shinichi Imafuku ◽

Hidemi Nakagawa ◽

Atsuyuki Igarashi ◽

Akimichi Morita ◽

Yukari Okubo ◽

...

Keyword(s):

Plaque Psoriasis ◽

Japanese Patients ◽

Efficacy And Safety ◽

Phase 3 ◽

Severe Plaque Psoriasis ◽

Download Full-text

Long‐term efficacy and safety of risankizumab for the treatment of moderate‐to‐severe plaque psoriasis: interim analysis of the LIMMitless open‐label extension trial beyond 3 years of follow‐up

British Journal of Dermatology ◽

10.1111/bjd.20595 ◽

2021 ◽

Author(s):

K.A. Papp ◽

M.G. Lebwohl ◽

L. Puig ◽

M. Ohtsuki ◽

S. Beissert ◽

...

Keyword(s):

Plaque Psoriasis ◽

Interim Analysis ◽

Efficacy And Safety ◽

Severe Plaque Psoriasis ◽

Term Efficacy ◽

Open Label Extension ◽

Extension Trial

Download Full-text

Long-term efficacy and safety of ixekizumab for the treatment of moderate-to-severe plaque psoriasis sustained for three years: Results of a randomized controlled phase 3 study (UNCOVER-3)

Journal of the American Academy of Dermatology ◽

10.1016/j.jaad.2018.05.732 ◽

2018 ◽

Vol 79 (3) ◽

pp. AB180

Keyword(s):

Plaque Psoriasis ◽

Efficacy And Safety ◽

Phase 3 ◽

Severe Plaque Psoriasis ◽

Randomized Controlled ◽

Download Full-text

Long-term efficacy and safety of fingolimod in Japanese patients with relapsing multiple sclerosis: 3-year results of the phase 2 extension study

BMC Neurology ◽

10.1186/s12883-017-0794-5 ◽

2017 ◽

Vol 17 (1) ◽

Author(s):

Takahiko Saida ◽

Yasuto Itoyama ◽

Seiji Kikuchi ◽

Qi Hao ◽

Takayoshi Kurosawa ◽

...

Keyword(s):

Multiple Sclerosis ◽

Japanese Patients ◽

Extension Study ◽

Phase 2 ◽

Efficacy And Safety ◽

Term Efficacy ◽

Relapsing Multiple Sclerosis

Download Full-text

Long-term efficacy and safety of eculizumab in Japanese patients with generalized myasthenia gravis: A subgroup analysis of the REGAIN open-label extension study

Journal of the Neurological Sciences ◽

10.1016/j.jns.2019.08.004 ◽

2019 ◽

Vol 407 ◽

pp. 116419 ◽

Author(s):

Hiroyuki Murai ◽

Akiyuki Uzawa ◽

Yasushi Suzuki ◽

Tomihiro Imai ◽

Hirokazu Shiraishi ◽

...

Keyword(s):

Myasthenia Gravis ◽

Subgroup Analysis ◽

Japanese Patients ◽

Extension Study ◽

Efficacy And Safety ◽

Term Efficacy ◽

Open Label Extension

Download Full-text

Efficacy and safety of alogliptin in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, dose-ranging comparison with placebo, followed by a long-term extension study

Current Medical Research and Opinion ◽

10.1185/03007995.2011.599371 ◽

2011 ◽

Vol 27 (9) ◽

pp. 1781-1792 ◽

Author(s):

Yutaka Seino ◽

Tetsuya Fujita ◽

Shinzo Hiroi ◽

Masashi Hirayama ◽

Kohei Kaku

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Type 2 Diabetes Mellitus ◽

Japanese Patients ◽

Extension Study ◽

Efficacy And Safety ◽

Double Blind ◽

Download Full-text

Efficacy and safety of alogliptin added to sulfonylurea in Japanese patients with type 2 diabetes: A randomized, double-blind, placebo-controlled trial with an open-label, long-term extension study

Journal of Diabetes Investigation ◽

10.1111/j.2040-1124.2012.00226.x ◽

2012 ◽

Vol 3 (6) ◽

pp. 517-525 ◽

Author(s):

Yutaka Seino ◽

Shinzo Hiroi ◽

Masashi Hirayama ◽

Kohei Kaku

Keyword(s):

Type 2 Diabetes ◽

Controlled Trial ◽

Japanese Patients ◽

Extension Study ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

Efficacy and safety of alogliptin added to pioglitazone in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial with an open-label long-term extension study

Diabetes Obesity and Metabolism ◽

10.1111/j.1463-1326.2011.01460.x ◽

2011 ◽

Vol 13 (11) ◽

pp. 1028-1035 ◽

Author(s):

K. Kaku ◽

T. Itayasu ◽

S. Hiroi ◽

M. Hirayama ◽

Y. Seino

Keyword(s):

Type 2 Diabetes ◽

Controlled Trial ◽

Japanese Patients ◽

Extension Study ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

Long-term efficacy and safety of itolizumab in patients with moderate-to-severe chronic plaque psoriasis: A double-blind, randomized-withdrawal, placebo-controlled study

Journal of the American Academy of Dermatology ◽

10.1016/j.jaad.2015.03.040 ◽

2015 ◽

Vol 73 (2) ◽

pp. 331-333.e1 ◽

Author(s):

Sunil Dogra ◽

Krupashankar D.S. ◽

Leelavathy Budamakuntla ◽

C.R. Srinivas ◽

Uday Khopkar ◽

...

Keyword(s):

Plaque Psoriasis ◽

Controlled Study ◽

Efficacy And Safety ◽

Chronic Plaque Psoriasis ◽

Double Blind ◽

Download Full-text

Sustained long‐term efficacy and safety of adalimumab in paediatric patients with severe chronic plaque psoriasis from a randomized, double‐blind, phase III study

British Journal of Dermatology ◽

10.1111/bjd.18029 ◽

2019 ◽

Vol 181 (6) ◽

pp. 1177-1189 ◽

Author(s):

D. Thaçi ◽

K. Papp ◽

D. Marcoux ◽

L. Weibel ◽

A. Pinter ◽

...

Keyword(s):

Plaque Psoriasis ◽

Phase Iii ◽

Efficacy And Safety ◽

Chronic Plaque Psoriasis ◽

Double Blind ◽

Term Efficacy ◽

Paediatric Patients ◽

Phase Iii Study

Download Full-text